8-K: Henry Schein Reports Strong Q4 and Full Year 2024 Results, Provides 2025 Guidance

Henry Schein reports positive Q4 and full-year 2024 financial results, with increased operating cash flow and provides 2025 financial guidance, including expected non-GAAP diluted EPS of $4.80 to $4.94.

Summary

• Henry Schein reported its fourth quarter and full year 2024 financial results on February 25, 2025.
• Fourth-quarter net sales were $3.2 billion, a 5.8% increase compared to Q4 2023.
• Full-year net sales reached $12.7 billion, a 2.7% increase compared to the previous year.
• The company's Q4 GAAP diluted EPS was $0.74, while non-GAAP diluted EPS was $1.19.
• Full-year GAAP diluted EPS was $3.05, and non-GAAP diluted EPS was $4.74.
• Operating cash flow for the quarter was $204 million, and for the full year, it was $848 million, up $348 million from 2023.
• Adjusted EBITDA for the quarter was $270 million, and for the full year, it was $1,061 million.
• Henry Schein expects 2025 non-GAAP diluted EPS to be in the range of $4.80 to $4.94.
• Total sales growth for 2025 is projected to be approximately 2% to 4% over 2024.
• Adjusted EBITDA growth for 2025 is expected to increase mid-single digits compared with 2024.
• The company repurchased approximately 1.1 million shares of its common stock during the fourth quarter at an average price of $71.35 per share, totaling $75 million.
• For the full year 2024, the company repurchased approximately 5.4 million shares at an average price of $71.04 per share, totaling $385 million.
• As of year-end, Henry Schein had $380 million authorized and available for future stock repurchases, with an additional $500 million authorized by the Board of Directors on January 27, 2025.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with solid financial results and forward guidance. While there are some negative aspects, such as the decrease in GAAP net income, the overall tone is optimistic due to increased sales, operating cash flow, and strategic initiatives.

Positives

• Fourth-quarter net sales increased by 5.8% compared to Q4 2023, reaching $3.2 billion.
• Full-year net sales increased by 2.7% compared to 2023, totaling $12.7 billion.
• Operating cash flow for the full year increased significantly, up $348 million compared to 2023.
• The company is projecting positive growth for 2025, with expected non-GAAP diluted EPS between $4.80 and $4.94.
• The company is actively repurchasing shares, indicating confidence in its financial position.
• The company is simplifying its organizational structure and appointed Andrea Albertini and Tom Popeck to be responsible for our three business groups.

Negatives

• Full-year 2024 GAAP net income decreased compared to 2023, from $416 million to $390 million.
• Internal sales growth for the full year decreased by 0.4%, although excluding PPE and COVID test kits, it increased by 0.3%.

Risks

• The company's forward-looking statements are subject to risks and uncertainties, including economic conditions, competition, and regulatory changes.
• The company is dependent on third parties for manufacturing and supply of products.
• The company faces risks related to cyberattacks and data security breaches, as highlighted by the October 2023 incident.
• The company is exposed to risks associated with global operations, including geopolitical events and changes in foreign trade policies.

Future Outlook

Henry Schein expects 2025 non-GAAP diluted EPS to be in the range of $4.80 to $4.94, with total sales growth of approximately 2% to 4% and Adjusted EBITDA growth increasing mid-single digits.

Management Comments

• Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein, stated that the company exceeded its 2024 target of generating 40% of its worldwide operating income from high-growth, high-margin businesses.
• Mr. Bergman added that the company expects 2025 to be the base year from which to grow and achieve its long-term goal of high-single digit to low-double digit earnings growth.
• Mr. Bergman continued, 'We expect that these complementary businesses will drive growth by leveraging our current product portfolio across our customer base, providing new products and services to our customers, and growing our e-Commerce business.'

Industry Context

Henry Schein's results reflect the overall stability in the dental and medical end-markets. The company's strategic focus on high-growth, high-margin businesses aligns with industry trends towards value-added services and technology solutions.

Comparison to Industry Standards

• Comparing Henry Schein to similar distributors like McKesson Corporation (MCK) and Cardinal Health (CAH), Henry Schein's revenue growth of 2.7% is within the range of these companies.
• McKesson reported a revenue increase of 11% in their most recent quarter, while Cardinal Health reported a revenue increase of 12%.
• However, it's important to note that these companies operate in different segments of the healthcare industry, with McKesson and Cardinal Health focusing more on pharmaceutical distribution.
• Henry Schein's focus on dental and medical practitioners provides a unique market position compared to these broader healthcare distributors.
• When comparing EBITDA margins, Henry Schein's Adjusted EBITDA margin of approximately 8.3% is comparable to industry standards for healthcare distributors.
• For example, McKesson's adjusted operating margin is around 3%, while Cardinal Health's is around 2%.
• However, direct comparison is difficult due to differences in accounting practices and business mix.

Management Changes

Corporate Governance

Legal Proceedings

• The company is addressing estimated settlement amounts for litigation related to the October 2023 cyber incident and settlement of certain opioid related lawsuits during YTD 2024.

Stakeholder Impact

• Shareholders can expect continued share repurchases and potential earnings growth.
• Customers will benefit from the company's focus on improving operational success and clinical outcomes.
• Employees may experience changes due to the restructuring plan, but also opportunities for growth within the new organizational structure.

Next Steps

• The company will hold a conference call to discuss fourth-quarter 2024 financial results.
• The company will continue to execute its 2025 to 2027 BOLD+1 Strategic Plan.
• The company intends to use part of the $500 million authorized by the Companys Board of Directors on January 27, 2025, to repurchase $250 million shares under an Accelerated Share Repurchase program.

Key Dates

Keywords

financial results, Henry Schein, EPS, EBITDA, sales growth, share repurchase, financial guidance, healthcare solutions, dental, medical